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Marked Expansion of Exocrine and Endocrine Pancreas
With Incretin Therapy in Humans With Increased
Exocrine Pancreas Dysplasia and the Potential for
Glucagon-Producing Neuroendocrine Tumors
Alexandra E. Butler,1 Martha Campbell-Thompson,2 Tatyana Gurlo,1 David W. Dawson,3
Mark Atkinson,2 and Peter C. Butler1
Controversy exists regarding the potential regenerative influen-
ces of incretin therapy on pancreatic b-cells versus possible ad-
verse pancreatic proliferative effects. Examination of pancreata
from age-matched organ donors with type 2 diabetes mellitus
(DM) treated by incretin therapy (n = 8) or other therapy (n =
12) and nondiabetic control subjects (n = 14) reveals an ;40%
increased pancreatic mass in DM treated with incretin therapy,
with both increased exocrine cell proliferation (P , 0.0001) and
dysplasia (increased pancreatic intraepithelial neoplasia, P ,
0.01). Pancreata in DM treated with incretin therapy were notable
for a-cell hyperplasia and glucagon-expressing microadenomas
(3 of 8) and a neuroendocrine tumor. b-Cell mass was reduced
by ;60% in those with DM, yet a sixfold increase was observed in
incretin-treated subjects, although DM persisted. Endocrine cells
costaining for insulin and glucagon were increased in DM com-
pared with non-DM control subjects (P , 0.05) and markedly
further increased by incretin therapy (P , 0.05). In conclusion,
incretin therapy in humans resulted in a marked expansion of the
exocrine and endocrine pancreatic compartments, the former
being accompanied by increased proliferation and dysplasia
and the latter by a-cell hyperplasia with the potential for evolu-
tion into neuroendocrine tumors. Diabetes 62:2595–2604, 2013
Type 2 diabetes mellitus (DM) is characterized bydefective insulin secretion in the setting of in-sulin resistance, leading to hyperglycemia. Thisdefect in insulin secretion is accompanied by
a deficit in b-cell mass. However, the extent and relevance
of this b-cell deficit has been questioned, in part due to the
paucity of human pancreatic studies as well as to meth-
odological differences among such efforts (1–3). Thera-
peutic hope for DM has recently been raised by the
introduction of a glucagon-like peptide-1 (GLP-1) mimetic
class of drugs widely referred to as incretins. Interestingly,
beyond their effects on improved metabolic regulation,
GLP-1 mimetic therapy was also noted to induce b-cell
regeneration in rodents, thus portending the remarkable
notion that the deficit in b-cell mass in DM might be
overcome with such agents (4–7). However, given this
ability was most evident in the period coincident with the
postnatal expansion of b-cell mass in rodents, questions
arose as to the relevance of this property of GLP-1 in adult
humans (8,9). Moreover, b-cell replication was not detected
in human islets exposed to high concentrations of GLP-1
in vitro (10). In contrast, there are concerns that the pro-
proliferative actions of GLP-1 might induce deleterious
effects on the exocrine pancreas, in which the capacity for
the proproliferative actions of GLP-1 appears to be better
retained into adult life (5,11,12).
To address this, we analyzed a series of high-quality (i.e.,
transplant grade) human pancreata obtained from brain-
dead organ donors with and without DM, including a sub-
group of the latter who underwent $1 year of incretin
therapy (13). Our goals were to confirm that b-cell mass
was indeed decreased with DM overall and to establish
whether incretin therapy induced an expansion of the
endocrine and/or exocrine pancreas.
RESEARCH DESIGN AND METHODS
Study subjects. All pancreata were procured from brain-dead organ donors by
the JDRF Network for Pancreatic Organ Donors with Diabetes (nPOD)
coordinated through the University of Florida in Gainesville, Florida (Table 1)
(13). All procedures were in accordance with federal guidelines for organ
donation and the University of Florida Institutional Review Board. Pancreata
were procured from 20 individuals with DM. These were subdivided into 12
who did not receive GLP-1 drugs (DM) and 8 who received incretin therapy
(DM-I) for 1 year or more, 7 being treated with the dipeptidyl peptidase-4
(DPP-4) inhibitor sitagliptin (Januvia) and 1 with the GLP-1 mimetic exenatide
(Byetta). Pancreata were also obtained from 14 nondiabetic (ND) control
subjects matched by age, sex, and BMI with the two DM treatment groups.
Pancreas fixation, embedding, and sectioning. nPOD uses a standardized
preparation procedure for pancreata recovered from cadaveric organ donors
(13). The pancreas is divided into three main regions (head, body, and tail),
followed by serial transverse sections throughout the medial to lateral axis,
allowing for sampling of the entire pancreas organ while maintaining ana-
tomical orientation. Because preparation is completed within 2 h, tissue in-
tegrity is maintained. Tissues intended for paraffin blocks are trimmed to
pieces no larger than 1.5 3 1.5 cm and fixed in 10% neutral buffered formalin
for 24 6 8 h. Fixation is terminated by transfer to 70% ethanol, and samples
are subsequently processed and embedded in paraffin. Mounted transverse
sections were obtained from the head, body, and tail of the paraffin-embedded
tissue blocks.
Immunostaining
In Florida. Formalin-fixed paraffin-embedded sections were stained according
to established procedures, as previously described (14). In brief, serial sections
(4 mm) were deparaffinized and incubated with primary antibodies to Ki67 and
insulin, or CD3 and glucagon, with antibody localization visualized with per-
oxidase-DAB and alkaline phosphatase-Fast Red polymer systems. Assays
included positive and negative controls for each antibody, and new lots of
reagents were validated to reproduce previous staining intensities using
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normal human spleen for Ki67 and CD3 and pancreata from the ND donors for
insulin and glucagon.
In Los Angeles. Sequential paraffin tissue sections from each region of
pancreas from each subject were stained for 1) Ki67, insulin, and Alcian blue
by immunohistochemistry and 2) Ki67 and glucagon by immunohistochemis-
try. In addition, a section of pancreas from each of the DM-I subjects and
a section from a subset of the DM subjects not treated with incretin therapy
(n = 5) and ND subjects (n = 6) were stained for insulin and glucagon by
immunofluorescence and additional sections for glucagon, insulin, cytoker-
atin, and DAPI.
Briefly, the cytokeratin, insulin, and glucagon slides were stained as follows:
CK-19 (mouse 1:50, 4ºC overnight; Dako, Carpinteria, CA), glucagon (rabbit
1:1000, 4ºC overnight; ImmunoStar Inc, Hudson, WI), and insulin (guinea pig 1:100,
4ºC overnight; Invitrogen, Grand Isle, NY). FITC, Cy3, and Cy5 followed incuba-
tion of each primary antibody, respectively (1:100, The Jackson Laboratory–
West, Sacramento, CA). Slides were coverslipped with Vectashield with DAPI
(Vector Laboratories, Burlingame, CA).
Morphometric analysis
In Florida. Stained slides were scanned to create whole digital slide images
with an Aperio ScanScope CS (Aperio Technologies, Vista, CA) and Spectrum
Plus version 11 at320 magnification. Each image was reviewed and annotated
using the Aperio ImageScope image viewing program. Regions with edge
artifact or nonspecific staining were excluded from analysis. The Spectrum
colocalization algorithm was used to estimate the proportion of insulin- and
glucagon-stained area compared with total tissue area defined by the hema-
toxylin counterstain. Software parameter settings were optimized for de-
tection of both hematoxylin and Fast Red chromogen. Data were averaged
within regions and then averaged among all regions for a given donor pan-
creas. Cytonuclear IHC quantification software (Indica Laboratories, Albu-
querque, NM) was used to quantify total cell numbers per pancreas section
and total cell replication rates using Ki67 nuclear immunopositivity. Input
parameters were set using an ImageScope plug-in tool that calculates optical
densities of the underlying structures in RGB OD values. Total cell counts
were estimated from nuclei stained with hematoxylin. Nuclei costained with
Ki67 were counted and expressed as a percentage of the total.
In Los Angeles. Whole sections of pancreas stained for insulin, Ki-67, and
Alcian Blue and hematoxylin counterstain were digitally scanned using Aperio
ScanScope. Analysis was performed using Aperio ImageScope version 11.0.2.725.
With this software, the total area of the tissue was measured.
Full cross-sections of the pancreas head, body, and tail were evaluated for
pancreatic intraepithelial neoplasia (PanIN) by a gastrointestinal pathologist
blinded to clinical information and using the established consensus classifi-
cation system for these precursor lesions (15). The total number of PanIN
lesions and their grade were determined per lobular unit and scored as the
highest-grade lesion within that lobule. The number of PanINs per pancreas
section was then computed per unit area of pancreas (mm2 3 103).
TABLE 1
Clinical characteristics of brain-dead organ donors
Age Duration of DM BMI
Case (years) (years) Sex (kg/m2) Treatments Cause of death
DM-I
6157 74 1 F 39 Januvia ICH/stroke
6185 46 15 M 41 Januvia, metformin Anoxia
6186 68 5 M 21 Januvia, metformin ICH/stroke
6189 49 26 F 36 Byetta, metformin, glipizide Stroke
6199 53 20 M 30 Januvia, insulin pen ICH/stroke
6194 47 13 M 24 Humulin, NovoLog, Januvia ICH/stroke
6203 68 5 M 33 Januvia, metformin Stroke
6206 59 10 M 42 Januvia, metformin Stroke
Mean (SEM) 58 (4) 12 (3) 33 (3)
DM
6028 33 17 M 30 Insulin Gunshot wound to head
6059 18 0.3 F 39 None Cardiovascular
6108 57 2 M 30 Metformin ICH/stroke
6110 20 0.2 F 40 None ICH/stroke, DKA
6109 48 — F 33 None ICH/stroke, DKA
6114 42 2 M 31 Metformin, noncompliant Asphyxiation
6124 62 3 M 34 Metformin ICH/stroke
6127 44 10 F 30 Insulin ICH/stroke
6133 45 20 F 40 Insulin Cardiovascular
6139 37 1.5 F 45 None Seizure
6142 29 14 F 34 None Bacterial meningitis
6149 39 20 F 29 Insulin ICH/stroke
Mean (SEM) 40 (4) 8 (3) 35 (2)
ND
6009 45 M 31 Anoxia
6015 39 F 32 Anoxia
6012 64 F 31 Cerebrovascular/stroke
6016 42 M 31 Cerebrovascular/stroke
6019 68 F 24 Head trauma
6020 60 M 30 Cerebrovascular/stroke
6022 75 M 31 Cerebrovascular/stroke
6034 32 F 25 Head trauma
6060 24 M 33 Head trauma
6097 43 F 36 Cerebrovascular/stroke
6099 14 M 30 Head trauma
6102 45 F 35 Cerebrovascular/stroke
6158 40 M 30 Head trauma
6165 45 F 25 Cerebrovascular/stroke
Mean (SEM) 45 (5) 30 (1)
DKA, diabetic ketoacidosis; F, female; ICH, intracerebral hemorrhage; M, male.
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Using the insulin-, Ki-67–, and Alcian blue–stained sections, 100 islets were
analyzed per section, with an Olympus CX41 microscope (Olympus America,
Center Valley, PA), to determine the frequency of Ki67 in the b-cells of islets
and in the non–b-cell compartment of those islets. Similarly, using the glucagon-
and Ki-67–stained sections, 100 islets per section were analyzed to determine
the frequency of Ki67 in the a-cells of islets and in the non–a-cell compartment
of those islets. The mean b- and a-cell diameter was determined in each in-
dividual using the insulin and glucagon immunostained sections from the
pancreas body, as previously described (16). A total of 475 a-cells and 475
b-cells were evaluated.
To determine the percentage of b- and a-cells within pancreatic ducts, the
insulin-Ki67-Alcian blue–stained slides and the glucagon-Ki67-hematoxylin–
stained slides were used. The total number of duct cells per pancreatic section
was counted manually, as was the total number of cells within the ducts that
stained for insulin or glucagon, respectively. The results are expressed as the
percentage of duct cells positive for insulin or glucagon.
Using the sections stained by immunofluorescence for insulin, glucagon, and
DAPI, a minimum of 30 islets per section (range 31–45, mean 38.0 6 1.0) were
randomly selected, imaged at 320 magnification, and stored using a Leica
DM6000 fluorescent microscope (Leica Microsystems, Deerfield, IL) con-
nected to a Macintosh computer loaded with Openlab software (Improvision,
Lexington, MA). Each islet was analyzed to determine the number of b-cells,
a-cells, and cells costaining for insulin and glucagon.
Confocal microscopy was performed where cells costaining for insulin and
glucagon were detected for confirmation that insulin and glucagon granules
were indeed both present in the same cells. Imaging was performed using
a scanning confocal microscope equipped with argon, green and red helium-
neon lasers (Leica). Images were acquired by sequential scanning using a 320
objective and the appropriate filter combination. Z sections were captured
with a 0.25-mm step size.
Statistical analysis. Statistical analysis was performed using the Student t test
with GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA). Data in
graphs and tables are presented as means 6 SEM. Findings were assumed
statistically significant at P , 0.05.
RESULTS
Pancreatic mass was increased (P , 0.05) ;40% in DM-I
patients compared with that in individuals with DM not
treated with such agents (Fig. 1A). The pancreatic fractional
insulin area was ;60% reduced in DM patients not treated
with incretin therapy compared with ND control subjects
(0.34 6 0.10 vs. 0.79 6 0.10%; P , 0.001) (Fig. 1B). In
contrast, the pancreatic fractional insulin area was ap-
proximately fivefold increased in DM-I patients compared
with individuals not treated with incretin therapy (1.60 6
0.41 vs. 0.34 6 0.10%; P , 0.0001).
The b-cell mass, computed from the product of the pan-
creatic fractional insulin-positive area and pancreatic mass,
was 55% decreased in DM patients not on incretin therapy
in comparison with ND control subjects (0.29 6 0.08 vs.
0.60 6 0.10 g; P , 0.05) (Fig. 1D). In contrast, b-cell mass
was increased sixfold in DM-I patients (1.81 6 0.56 vs.
0.29 6 0.08 g; P , 0.01). Moreover, b-cell mass was three-
fold greater in DM-I individuals compared with ND control
subjects (1.81 6 0.56 vs. 0.60 6 0.10 g; P , 0.05). The six-
fold increase in b-cell mass in DM-I subjects was almost all
due to increased b-cell numbers rather than b-cell size, al-
though there was a 3% increase in b-cell size with incretin
therapy (8.9 6 0.1 vs. 8.6 6 0.1 mm, DM vs. DM-I; P , 0.05)
(Fig. 1C). The pancreatic fractional area immunostained for
glucagon was comparable between DM individuals not
subject to incretin therapy and ND control subjects (0.57 6
0.12 vs. 0.52 6 0.08%; P = NS) (Fig. 1E). However, the
pancreatic fractional area immunostained for glucagon was
markedly increased in DM-I individuals compared with DM
patients on other therapy (1.65 6 0.39 vs. 0.576 0.12%; P ,
0.0001) as well as compared with ND control subjects
(1.65 6 0.39 vs. 0.52 6 0.08%; P , 0.0001). The pattern of
the calculated glucagon mass followed that of the pancre-
atic fractional area, being comparable in individuals with
FIG. 1. Pancreas, b-cell, and a-cell mass. A: Mean pancreatic weight.
*P < 0.05 DM-I vs. DM. B: Pancreatic fractional insulin area. ***P <
0.0001 DM-I vs. DM, **P < 0.001 DM vs. ND. C: b-Cell diameter. *P <
0.05 DM-I vs. DM. D: b-Cell mass. ^P < 0.01 DM-I vs. DM, *P< 0.05 DM-
I vs. ND, *P < 0.05 DM vs. ND. E: Pancreatic fractional glucagon area.
***P < 0.0001 DM-I vs. DM and ND. F: a-Cell diameter. ^P < 0.01 DM-I
vs. DM, #P < 0.005 DM-I vs. ND. G: a-Cell mass. ^P < 0.01 DM-I vs. DM.
*P < 0.05 DM-I vs. ND. Pancreatic weight was 40% increased in DM-I
compared with DM (P < 0.05). b-Cell mass was decreased in DM
compared with ND but was approximately sixfold increased in DM-I
compared with DM. a-Cell mass was comparable in DM and ND but was
approximately fivefold increased in DM-I compared with DM. The in-
crease in b-cell and a-cell mass with incretin treatment was pre-
dominantly due to endocrine hyperplasia rather than hypertrophy.
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DM not treated with incretin therapy and control subjects,
but fivefold increased in DM-I individuals compared with
DM patients not treated with incretin therapy (2.08 6 0.75
vs. 0.45 6 0.10 g, DM-I vs. DM; P , 0.01) (Fig. 1G). The
marked increase in a-cell mass, like that of b-cell mass, was
almost completely due to an increase in the number of
a-cells, although again, there was a 4% increase in a-cell size
(8.96 0.1 vs. 8.66 0.1 mm, DM-I vs. DM; P, 0.01) (Fig. 1F).
There were two immediately striking findings on in-
spection of the pancreatic sections of the DM-I subjects:
a subset of enlarged and often eccentrically shaped islets
as well as increased numbers of endocrine cells in asso-
ciation with duct structures (Figs. 2–4). The impression of
a subset of enlarged islets was confirmed quantitatively,
the 12 largest islets per section in the DM-I subjects being
almost twice the cross-sectional area of those in the DM
subjects not treated by incretins (82,270 6 10,330 vs.
44,7706 6,986 mmol/L2; P, 0.01). While examples of insulin
immunoreactive cells related to ductal structures could be
found in individuals from all three groups, the percentage
of such cells within ducts was not increased in DM-I versus
DM subjects without incretin therapy (0.30 6 0.09 vs.
0.27 6 0.07%; P = NS) (Figs. 3 and 4). However, glucagon-
immunoreactive cells were frequently found in long linear
groups or solid nests of cells either within the duct itself
or in the immediate periductal location. In addition, these
glucagon-positive cells also formed intraductal luminal
projections, as previously described in chronic pancreati-
tis (17) (Fig. 2A). There were also regions with multiple
small ducts that had glucagon-expressing tubular- and
islet-like structures directly contiguous to the ducts. Of note,
there were cells expressing both cytokeratin and glucagon
at the interface of these a-cell tubular projections from
ducts (Fig. 2F–I). The percentage of cells immunoreactive
for glucagon in ducts was increased in DM-I versus DM
with no incretin therapy (2.8 6 0.9 vs. 0.5 6 0.2%; P , 0.05)
FIG. 2. Glucagon immunohistochemistry in pancreas in DM after incretin therapy. A–E: Sections of pancreas from DM-I donors (cases 6185, 6186,
6206, and 6203 with sitagliptin) immunostained for glucagon (pink) with hematoxylin counterstain. Exuberant expansion of glucagon immuno-
reactive cells is seen as enlarged eccentrically shaped islets as well as nodular and linear aggregates of cells intimately associated with ducts and
demonstrating variable extension into duct lumens (arrow). C–E: Higher-power images show glucagon immunoreactivity in cells lining ducts. F–I:
Pancreas sections from DM-I donors (case 6199, sitagliptin; 6189, exenatide) show immunofluorescent costaining for cytokeratin (green), glu-
cagon (red), and DAPI nuclear counterstain (blue). Glucagon-expressing cells are present within and adjacent to keratin-positive duct structures.
G: One cell costaining for cytokeratin and glucagon is indicated by the arrow.
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(Fig. 3E). Thus, while the exuberant increase in glucagon
immunoreactive cells with incretin treatment was frequently
observed in the periductal areas, the increased numbers of
insulin immunoreactive cells with incretin therapy tended to
be most abundant more remote from these periductal en-
docrine complexes (Fig. 3B and D). The pancreas from the
single individual treated with exenatide also revealed exu-
berant a-cell hyperplasia (Fig. 4).
In one individual with DM treated with sitagliptin (nPOD
case 6185), a 1.5-cm a-cell/glucagon-producing neuroen-
docrine tumor (grade 1, World Health Organization, 2010)
not appreciated in life was identified in the body of the
pancreas after resection at brain death (Fig. 5). Glucagon-
producing microadenomas were also detected in the same
individual (case 6185) and in two other DM-I individuals
(cases 6157 and 6206) (Supplementary Fig. 3), whereas
hyperplastic islets with predominant glucagon staining were
noted in seven of eight of the DM-I individuals. No neuro-
endocrine tumors or glucagon-producing microadenomas
were detected in ND control subjects or in DM subjects not
treated with incretin therapy.
Inspection of pancreatic sections immunostained with
either insulin or glucagon from the DM-I individuals gave
the impression that numerous cells within these islets were
immunoreactive for both hormones. When quantified in
sections double-immunostained for glucagon and insulin by
confocal microscopy for this purpose (Fig. 6, Supplemen-
tary Figs. 1 and 2), the percentage of insulin-positive cells in
DM-I individuals that were also glucagon immunoreactive
were indeed markedly increased when compared with
those with DM not treated with incretin therapy (16.8 6 5.0
vs. 3.2 6 1.4%; P , 0.05). Interestingly, there was also an
FIG. 3. Distribution of a-cells and b-cells in relation to ducts in DM-I donors. Serial adjacent sections of pancreas from DM-I donors (case 6189,
exenatide; 6185, sitagliptin) were immunostained for glucagon (A and C) or insulin (B and D) with hematoxylin counterstain. These serial sec-
tions indicate that the exuberant endocrine growth associated with ducts is predominantly comprised of glucagon immunoreactive cells. The
percentage of glucagon-positive cells in ducts (E) and insulin-positive cells in ducts (F) is shown. The percentage of glucagon-positive cells in
ducts was increased in the DM-I group compared with the DM and ND groups (*P < 0.05). In contrast, the percentage of insulin-positive cells in
ducts was unchanged in the DM-I group.
A.E. BUTLER AND ASSOCIATES
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increase in double immunoreactive-positive cells in indi-
viduals with DM not treated with incretin therapy when
compared with the ND control subjects (3.2 6 1.4 vs. 0.4 6
0.1%; P, 0.05). As in prior human studies (2), the frequency
of Ki67-positive nuclei in islet endocrine cells was ex-
tremely rare (all less than 0.01 cells per islet section), with
no significant differences in this very low frequency of b- or
a-cell replication among any of the three groups studied.
The increased pancreatic mass in DM induced by in-
cretin therapy was accompanied by increased whole pan-
creas cell proliferation (0.25 6 0.03 vs. 0.12 6 0.01%, DM-I
vs. DM; P , 0.0001) and an increase in the presence of
PanINs (11.9 6 2.6 vs. 4.9 6 1.7, DM-I vs. DM, PanINs/mm2
3 103; P , 0.01) (Fig. 7). PanIN lesions were also not in-
frequently detected in or close to these areas with ductular
a-cell complexes (Fig. 7). Inspection of pancreas sections
in DM-I individuals revealed small foci of increased Ki67
immunostaining in and around ducts and sometimes in
areas of exocrine dysplasia (Supplementary Fig. 4). Given
the focal and often dysplastic nature of these areas of in-
creased cell replication, it was not possible to attribute the
increased replication to a particular tissue compartment of
the pancreas (e.g., ducts, acinar cells).
DISCUSSION
In this study, we took advantage of the unique resource of
pancreata procured by the JDRF nPOD program (13) to
re-evaluate the question of b-cell mass in DM and, in ad-
dition, to address the potential actions of the incretin
drugs on the endocrine and exocrine compartments. In the
individuals with DM not using incretin drugs, we report
a 60% deficit in b-cell mass but unchanged a-cell mass.
Perhaps not surprisingly, given methodological differ-
ences, previous reports suggest a wide range of change in
b- and a-cell mass (or pancreatic fractional area) in DM
(1–3,18–20).
A striking finding in the present studies is the marked
expansion of the exocrine and endocrine compartments
of the pancreas with incretin therapy. The DPP-4 inhibitor
sitagliptin acts to increase endogenous GLP-1 levels (21).
It is not known whether the actions of sitagliptin reported
here were mediated by increased circulating GLP-1 lev-
els, increased GLP-1 levels produced by the newly formed
a-cells acting in a paracrine manner, or due to the actions
of signaling peptides other than GLP-1 that are degraded
by DPP-4. The one individual treated by exenatide avail-
able to us here showed a pattern of changes comparable
to those observed in the sitagliptin-treated individuals
(Fig. 4), implying that a direct action of GLP-1 is likely
involved. However, to fully address this question, it will
be important to obtain more pancreata from individuals
who have been treated with GLP-1 mimetic therapy.
The pancreatic mass of the DM-I individuals was in-
creased by 40% compared with patients with DM not
treated with incretin therapy, consistent with prior rodent
FIG. 4. Evidence for a direct role of GLP-1 mimetic action in a-cell hyperplasia. Images of pancreatic sections (A–F) are provided to illustrate
a similar pattern of a-cell hyperplasia in the donor treated with exenatide (6189) as in the sitagliptin-treated donors, implying a role for GLP-1
action independent of DPP-4 inhibition in a-cell hyperplasia. Enlarged and often eccentrically shaped islets are apparent, as well as increased
numbers of glucagon immunoreactive cells associated with and surrounding ductal structures.
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studies that revealed proliferative actions of GLP-1 on the
exocrine pancreas now extended here to humans (5,12).
Also of particular concern, incretin therapy was associated
with an increase in pancreatic dysplastic PanIN lesions,
consistent with the prior finding that GLP-1 receptors are
expressed not only in the human exocrine pancreas but
also in PanINs and that GLP-1 induces proliferative sig-
naling in human pancreatic duct epithelial cells (12).
Moreover, GLP-1 accelerated mPanIN formation in the
KrasG12D mouse model (12). Of interest, PanINs and ductal
endocrine complexes in DM-I donors were often seen in
close proximity (Fig. 7), which could suggest a common
underlying dysplastic process that perhaps adds insight
into the admixture of endocrine cells often noted within
pancreatic adenocarcinoma (22). The increased cellular
proliferation observed in the whole pancreas sections of
DM-I patients (Fig. 7E) could theoretically be due to
a contribution of intrapancreatic GLP-1 released by newly
formed a-cells. It is unlikely that brain-dead individuals in
an intensive care unit setting for the week before organ
procurement would be treated by incretin therapy. To
more precisely elucidate the direct action of those thera-
pies on proliferation in the human pancreas and to inves-
tigate the cellular subcompartments in which they induce
this action, it will also be important to seek opportunities
to obtain pancreata from individuals who had incretin
therapy up until the pancreas was obtained, perhaps via
surgery.
The marked a-cell hyperplasia, glucagon-expressing
microadenomas, and glucagon-expressing neuroendocrine
tumor noted in DM-I individuals are also of concern. These
findings reproduce the a-cell hyperplasia, abnormal a-cell
distribution, and predisposition to glucagon-expressing neu-
roendocrine tumors previously reported with suppressed
glucagon secretion or signaling (23–25). It is of note that
a consistent action of incretin therapy is to suppress glu-
cagon secretion. As in prior reports of decreased glucagon
secretion or action, the expansion in a-cell mass in DM-I
subjects was prominently distributed as tubular outgrowths
of glucagon-expressing cells from small duct-like structures
within the lining of (or surrounding) larger ducts occa-
sionally forming intraductal projections within the lumen.
The latter possibly contribute to the reported increased
incidence of pancreatitis in incretin-treated patients (11).
Pancreatitis has previously been reported in humans with
unexplained a-cell hyperplasia (26), and intraductal en-
docrine cell projections have been reported previously
in chronic pancreatitis (17). Therefore, incretin therapy–
induced intra- and periductal a-cell proliferations are now
added to incretin therapy–induced expansion of PanIN
lesions as plausible mechanistic links to the induction of
pancreatitis through obstruction of the outflow of pan-
creatic enzymes.
The source of new a-cells in prior studies of impaired
glucagon secretion or signaling was deemed most likely as
arising from progenitor cells because no increase in a-cell
replication was detected (23–25). We were also unable to
detect any increase in a-cell replication in DM-I specimens
to account for a-cell hyperplasia. Although again it should
be noted that the study subjects were likely not exposed to
incretin drugs immediately before pancreas procurement,
a prior study suggests that sitagliptin therapy suppresses
rather than enhances a-cell replication (27). Given that
a-cells are epigenetically relatively unstable (28) and that
most glucagonomas display malignant behavior, the pres-
ent finding calls into question the safety of long-term
suppression of glucagon secretion or action. Moreover,
because the standard of care of a pancreatic neuroendo-
crine tumor is surgical resection, due to the risk of con-
version to malignancy, even if benign, patients exposed to
incretin therapy would seem to be at increased risk of
requiring pancreatic surgery.
The present finding of an increased pancreatic mass,
increased PanIN lesions, and endocrine proliferations
encircling and sometimes encroaching on pancreatic ducts
in response to GLP-1 mimetic therapy does add to con-
cerns already raised regarding the potential adverse
actions of GLP-1 mimetic therapy to induce pancreatitis
and accelerate pancreatic dysplasia (11). Prior reports of
potentially concerning pancreas changes with incretin
therapy were confined to studies of rodent pancreas but
are now here extended to humans with the added concern
of the risk of neuroendocrine tumors. Because newly
formed a-cells in response to impaired glucagon secretion
have been shown to secrete high levels of GLP-1 (23–25),
the local GLP-1 concentrations in the pancreas in patients
treated with DPP-4 inhibitors may be very high, particu-
larly where these cells are abundant in and around dys-
plastic ducts. This may account for the observed increase
in pancreatitis and pancreatic tumors registered with the
U.S. Food and Drug Administration’s adverse event
reporting system for GLP-1 mimetics and DPP-4 inhibitors,
in contrast to the signal for thyroid tumors being restricted
to GLP-1 mimetics (11). It also may explain the expansion
of the exocrine pancreas in glucagon receptor–null mice
(and mutant human), exocrine proliferation being noted in
both, as well as high GLP-1 release by newly formed
a-cells (23–25).
At first sight, the increase in b-cell mass with incretin
therapy in DM in ND subjects would appear to be an ex-
citing finding in relation to the potential for disease reversal.
FIG. 5. Pancreatic glucagon expressing neuroendocrine tumor and
microadenoma. Grossly visible lesion (A) and corresponding section
stained with hematoxylin and eosin (B) of the clinically undetected
glucagon-expressing neuroendocrine tumor in the pancreas of a DM-I
donor (nPOD case 6185) after sitagliptin therapy. Gross specimen (C)
and corresponding hematoxylin and eosin–stained section (D) of a
glucagon-expressing microadenoma in nPOD case 6206, DM after sita-
gliptin therapy. The inset shows high-power view of representative cells
stained for glucagon by immunohistochemistry. (See Supplementary
Fig. 3 for an additional image of microadenoma in case 6206.)
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Unfortunately, these insulin-expressing cells are pre-
sumably not functionally mature because the DM-I indi-
viduals still had DM. It will be important to establish the
molecular signature of the insulin-expressing cells in fu-
ture studies. The marked expansion of the b-cell mass in
individuals with DM treated with sitagliptin or exenatide
for a year or more is in contrast to the findings of the
effects of these drugs on b-cell function in DM (29,30).
Although b-cell function benefits to some extent in
patients with DM with any therapy that lowers blood glu-
cose values (31,32), no data to date suggest that there is
a disease-modifying action of incretin therapy in DM over
that of any other glucose-lowering agent with regard to
recovery of b-cell function (29,30). It is plausible that
GLP-1 directly induced proliferation of b-cells, as has been
reported in animal studies (4,5). However, these studies
were in juvenile rodents, and GLP-1 did not induce pro-
liferation in human islets in vitro (10). Also, b-cell repli-
cation did not differ among the groups in this study.
However, as stated previously, because incretin therapy
was likely not administered during the last week of life in
the present donors, it is not possible to exclude incretin-
induced b-cell replication from this study. Likewise, it is
conceivable that the increase in b-cell number in DM-I may
be due in part to GLP-1–mediated inhibition of b-cell ap-
optosis.
Another striking finding in the islets of the DM-I indi-
viduals is a high proportion of cells that expressed both
insulin and glucagon. This has been described in the newly
forming endocrine pancreas at week 20 of gestation in
humans (33) and thus might be an indication of newly
formed immature endocrine cells from presumptive pro-
genitors. Alternatively, lineage-tracing studies in diabetic
mice have established that a-cells have the capacity to
transdifferentiate toward a b-cell phenotype (34). A third
possible source of these double hormone–expressing cells
could be b-cells that have partially transdifferentiated toward
an a-cell fate. The epigenetic basis of this interconversion
has been established (35).
In summary, we confirm that in humans with DM, b-cell
mass is deficient while a-cell mass is no different from that
in ND individuals. We note that both the exocrine and
FIG. 6. Insulin and glucagon coexpression. Co-immunofluorescent images of islets from case 6185, sitagliptin (A–H) show endocrine cells coex-
pressing insulin (green) (A and E), glucagon (red) (B and F), and merged (D and H). The proportion of endocrine cells per islet that were thus
detected as coexpressing insulin and glucagon was markedly increased in DM-I. Confocal images are shown of an islet from case 6185 stained for
insulin (green) (I) and glucagon (red) (J), and a merged image (K) shows a mixture of cells, some expressing insulin or glucagon only (arrow-
heads) and some showing coexpression (arrows). DAPI nuclear counterstain (blue).
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endocrine pancreas are markedly enlarged in DM-I indi-
viduals, with increased exocrine cell proliferation. The
a-cell hyperplasia and neuroendocrine tumor and micro-
adenoma formation is consistent with chronic inhibition of
glucagon secretion by GLP-1. These findings lend addi-
tional weight to concerns regarding the effects of long-term
GLP-1–related therapy with respect to unintended pro-
liferative actions on the exocrine pancreas and now also
a possible increased risk of neuroendocrine tumors. In ad-
dition to the surveillance previously recommended for the
potential association of GLP-1–based therapy and pancre-
atic cancer risk, the current data imply that surveillance
for a possible increased risk of pancreatic neuroendo-
crine tumors is warranted. On the other hand, the finding
that there is a capacity to form large numbers of insulin-
expressing cells in adult humans offers an impetus to the
hopes of the goal of inducing b-cell regeneration in either
type 1 or 2 diabetes. It is clear that a priority will be to
establish the pathway by which these cells are formed
and how to favor an endocrine versus exocrine cell line-
age and, within the latter, a b-cell lineage. Moreover, fur-
ther investigation on how to foster the maturation of the
newly formed b-cells to function is of vital therapeutic
importance.
FIG. 7. Pancreatic intraepithelial neoplasia, endocrine complexes, and cellular replication. Photomicrographs show sections with immunohisto-
chemical staining for Ki67 (brown) and glucagon (pink) in PanIN lesions (A and C) with hematoxylin counterstain or Ki67 (brown) and insulin
(pink) (B and D) with Alcian blue counterstain to highlight mucin. Glucagon-expressing endocrine cells are shown intimately associated with
PanIN lesions to varying degrees. Foci of replication (arrows, Ki67 nuclei) are also apparent. (See Supplementary Fig. 4 for additional examples of
foci of increased replication in incretin treated pancreas.) E: Pancreas cell replication is increased in DM-I (Ki67). ***P < 0.0001 DM-I vs. DM and
ND. F: Frequency of PanIN1 and 2 (lesions/mm2 3103 of pancreas) is increased in DM-I. ^P < 0.01 DM-I vs. DM, ***P < 0.0001 DM-I vs. ND.
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